Marina Pavanello

Translational and Clinical Cancer Researcher

[Marina Pavanello @marinapavanell3]

Very excited to share our review of rare inherited mutations in #ovariancancer really focussing on the differences between each histotype. @UNSWMedicine

Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer https://t.co/MKE0SVxV1z via @MDPIOpenAccess

[Sociedade Portuguesa de Imunologia @SImunologia]

The first episode of the new podcast from the Portuguese Society for Immunology, where @BSilva_Santos discusses cancer immunotherapy, is now available – English version:

https://t.co/CB7O8Q3OCI

Please share! Thank you! 

[Dr Dale Garsed @DrDaleGarsed]

In a large international study of more than 7000 patients with #OvarianCancer, we found that combined loss of RB1 protein & BRCA gene mutation predicts 🔼 immunologic responses and long-term survival in the high-grade serous subtype. Online NOW @CCR_AACR https://t.co/Ujnm5Lz8bA

[Liz Christie @DrLizChristie]

Read the latest research from the Christie lab @PeterMacRes on MHCII and whole genome duplication in ovarian cancer, published with @SpringerNature in @NatureComms https://t.co/0nZEMq1ObW

[Nicki Meagher, PhD @MeagherNicki]

Great to speak with #9News yesterday along with @ocrfaustralia CEO Robin Penty on raising #ovariancancer awareness and much needed funds for research.

[Marina Pavanello @marinapavanell3]

@MeagherNicki @djmarsh24 @ocrfaustralia @DaffodilCentre @9NewsSyd @sophie_walsh9 You’re becoming a celebrity 🤭🤩 that’s awesome!!

[Marina Pavanello @marinapavanell3]

@DaffodilCentre @annapoids @nhmrc @WestmeadInst @CCNewSouthWales @syd_health Amazing news @annapoids 👏

[FORRT @FORRTproject]

We determined authorship order using the Academic Wheel of Privilege (adapted from @sylviaduckworth). We examined our degree of privilege/marginalization in academia and society through a scoring system. Authors with fewer “privileges points” were prioritized in the author list.

[Marina Pavanello @marinapavanell3]

Exploring rare ovarian cancer histotypes as part of an international collaboration. So important as these neglected groups of patients have limited risk predictions & treatment options. Check out our preprint for genetic insights and stay tuned for more!
https://t.co/4u2OtuCbQx

[Anniina Färkkilä @afarkkila]

What happens in the #tumormicroenvironment during chemotherapy in #ovariancancer ? Check out our new preprint: https://t.co/MEkPaTKlQU

[Marina Pavanello @marinapavanell3]

A great comment emphasizing the importance of using technologies that capture how tumour cells, immune cells, and the surrounding tissue interact in ovarian cancer.
https://t.co/r2SrNJfOEv

[Marina Pavanello @marinapavanell3]

Thrilled to contribute to this incredible project and grateful to our scientific journalist for sharing our work with a broader audience. Making research accessible to everyone is crucial! #ovariancancerawareness

https://t.co/enIulmsuBP

[Rob Swanda @ScientistSwanda]

NONE. ZERO. ZIP. NADA. 🎉

what a wonderful highlight to show the importance of HPV vaccination (critical for all genders) to halt the spread of deadly cancers.

[NatureRevClinOncol @NatRevClinOncol]

The FDA has approved pembrolizumab with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer, based on a PFS benefit demonstrated in the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial: https://t.co/tGz6fMmP0x

[Ming "Tommy" Tang @tangming2005]

Do you want to learn computation as a wet biologist? I shared my experience in this podcast https://t.co/qMxlK8numr by @singlecellworld

[Marina Pavanello @marinapavanell3]

Research continually evolves in amazing ways 👏

[nature @Nature]

Cancer-fighting CAR-T cells could be made inside body with viral injection https://t.co/q9YXa3AkCm

[Nature Medicine @NatureMedicine]

11 clinical trials that will shape medicine in 2024 - from base editing and a vaccine against HIV to AI tools for lung cancer and patient triage.

Part of our Year in Review, by Paul Webster and @edbites

https://t.co/yBfQUotnjZ

[Prof Francine Marques @FZMarques]

Excited to share my opinion piece on rethinking culture to unlock the potential of research

Grateful to @HyperAHA & editors @LabTouyz & @endocelldoc for the support

A 🧵 about why I wrote this & why it matters

https://t.co/uEo64Oulbx

[nature @Nature]

Falling behind: postdocs in their thirties tire of putting life on hold.

Read the results of Nature’s second global survey of postdoctoral researchers https://t.co/jYxKuLT3B9

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

🙌INTERLACE trial - induction chemotherapy + chemoXRT vs chemoXRT alone in locally advanced #CervicalCancer
✅🤩Compliance was good
Induction yielded increased
Progression free survival: HR 0.65 (p-0.013)
Overall survival: HR 0.61 (p=0.04)
#gyncsm #radonc #ESMO2023

[NatureRevClinOncol @NatRevClinOncol]

In a Review now published online, Ana Veneziani, Eduardo Gonzalez-Ochoa, Husam Alqaisi, Ainhoa Madariaga, Gita Bhat, Marjan Rouzbahman, Suku Sneha & Amit Oza provide a comprehensive overview on the heterogeneity and treatment landscape of #ovariancancer https://t.co/CKLnbBanGC